BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

IntraBiotics Pharmaceuticals, Inc. (IBPI) Reports Third Quarter 2004 Financial And Operating Results


10/19/2005 5:12:10 PM

PALO ALTO, Calif., Nov. 10 /PRNewswire-FirstCall/ -- IntraBiotics Pharmaceuticals, Inc. today reported financial and operating results for the third quarter and nine months ended September 30, 2004.

IntraBiotics reported a net loss applicable to common stockholders of $4.0 million for the third quarter of 2004, or $0.46 per basic and diluted share. Research and development expenditures totaled $2.1 million, due primarily to the winding-down of the discontinued clinical trial of iseganan for the prevention of VAP. General and administrative expenses totaled $1.1 million, and a restructuring charge of $0.8 million was recorded for involuntary employee termination benefits, the termination of operating leases and the write-off of leasehold improvements.

In June 2004, we discontinued our clinical trial of iseganan for the prevention of VAP following a recommendation of the independent data monitoring committee. We have since terminated our iseganan development program, and are now evaluating our strategic options, including mergers, acquisitions, in-licensing opportunities, and liquidation of the Company.

On September 30, 2004, the Company had a total of $53.3 million in cash, cash equivalents, restricted cash and short-term investments. Current liabilities totaled $2.0 million. The Company has no long-term debt or other long-term obligations. Based upon currently projected expenses for the remainder of 2004, the Company expects to have available cash and investments of between approximately $46 million and $50 million at December 31, 2004, after providing for current liabilities. There can be no assurance that such a range will be achieved, as actual expenditures may differ significantly from projected expenditures.

Approximately 10.6 million common equivalent shares were issued and outstanding on September 30, 2004, including 1.7 million shares underlying outstanding convertible preferred stock. Assuming the net exercise of in-the-money warrants and options at the closing price of the Company's stock as quoted on the Nasdaq National Market as of September 30, 2004, approximately 11.2 million common equivalent shares would be outstanding on September 30, 2004.

The foregoing statements regarding anticipated cash and investments at year-end are forward-looking. Actual results could differ materially, depending on a variety of factors, including the following: actual expenses incurred in terminating the clinical trials; fluctuations in headcount; costs associated with pursuing various strategic alternatives, and pending litigation. Moreover, the enumeration of potential strategic alternatives in this release does not mean that the Company will be able to achieve any of them successfully.

IntraBiotics Pharmaceuticals, Inc. Statements of Operations (In thousands, except per share amounts) (Unaudited) THREE MONTHS ENDED NINE MONTHS ENDED SEPTEMBER 30, SEPTEMBER 30, 2004 2003 2004 2003 Operating expenses: Research and development $ 2,146 $ 3,641 $ 11,019 $ 5,261 General and administrative 1,070 1,125 3,759 3,833 Restructuring charge 791 -- 791 -- Total operating expenses 4,007 4,766 15,569 9,094 Operating loss (4,007) (4,766) (15,569) (9,094) Interest income 221 28 408 99 Other expense (175) -- (175) -- Net loss (3,961) (4,738) (15,336) (8,995) Non-cash deemed dividend related to beneficial conversion feature of Series A preferred stock -- -- -- (1,418) Dividends on Series A preferred stock (65) (70) (195) (117) Net loss applicable to common stockholders $(4,026) $(4,808) $(15,531) $(10,530) Basic and diluted net loss per share applicable to common stockholders $ (0.46) $(1.46) $ (2.18) $ (3.22) Shares used to compute basic and diluted net loss per share applicable to common stockholders 8,844 3,283 7,121 3,274 IntraBiotics Pharmaceuticals, Inc. Condensed Balance Sheet Data (In thousands) (Unaudited) SEPTEMBER 30, DECEMBER 31, 2004 2003 Cash, cash equivalents, short term investments and restricted cash $53,332 $26,644 Total assets 53,810 27,326 Total stockholders' equity $51,830 $25,628

IntraBiotics Pharmaceuticals, Inc.

CONTACT: investors, Kathleen Stafford of IntraBiotics Pharmaceuticals,Inc., +1-650-845-6204; or media, Carolyn Baumgartner of Weisscom Partners,Inc., +1-415-362-5018, for IntraBiotics Pharmaceuticals, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES